Carbamazepine, phenytoin, and valproic acid blood tests measure how much seizure medication is circulating in the blood at a specific moment. These medicines can be very effective, but they also have relatively narrow safety margins. A level that is too low may leave a person at risk for breakthrough seizures, while a level that is too high can cause dizziness, confusion, poor coordination, liver stress, low platelets, or more serious toxicity.
The number alone rarely tells the whole story. A seizure medication level must be interpreted with the dose, timing of the last dose, missed doses, other medicines, albumin level, liver function, kidney function, pregnancy status, symptoms, and seizure control. A “normal” result can still be wrong for a specific person, and an “abnormal” result may not always require an urgent dose change. The most useful interpretation combines the lab value with how the person is actually doing.
- Carbamazepine levels are commonly interpreted against a therapeutic range of about 4–12 mcg/mL.
- Phenytoin is usually assessed with a total range of about 10–20 mcg/mL, but free phenytoin is often more useful when albumin is low.
- Valproic acid is commonly interpreted around 50–100 mcg/mL for epilepsy, though some labs and situations use a higher upper range.
- Trough samples, drawn shortly before the next dose, are usually the easiest levels to compare over time.
- Urgent follow-up matters when a high level occurs with severe sleepiness, confusion, repeated vomiting, abnormal movements, worsening seizures, jaundice, bleeding, or trouble walking.
Table of Contents
- How Seizure Medication Levels Work
- Therapeutic Ranges and Toxic Patterns
- Timing and Sampling Issues
- Interpreting Low, Normal, and High Results
- Drug-Specific Patterns
- What Can Change Medication Levels
- Follow-Up Testing and Safety
- Common Mistakes and Next Steps
How Seizure Medication Levels Work
Carbamazepine, phenytoin, and valproic acid levels are therapeutic drug monitoring tests. They do not diagnose epilepsy. They measure medication exposure so clinicians can judge whether the current dose is likely to be effective, excessive, or unreliable.
These tests are most helpful when the result answers a specific clinical question, such as:
- Is the dose high enough to prevent seizures?
- Could dizziness, sleepiness, unsteady walking, tremor, or confusion be from medication toxicity?
- Did a missed dose, vomiting illness, or medication interaction change the level?
- Is the level different after pregnancy, weight change, liver disease, kidney disease, or a new prescription?
- Is the person taking the medicine consistently?
A level is usually reported in mcg/mL, which is the same as mg/L. Some labs also report micromol/L. The report may show a “therapeutic range,” but that range is not a perfect rule. It is a population-based guide. Some people have good seizure control below the listed range. Others need a level near the upper part of the range. Some develop side effects even when the reported level is technically “therapeutic.”
For many people, the most useful level is their own stable level during a period of good seizure control and minimal side effects. Once that personal reference point is known, later results can be compared against it. For example, a phenytoin level of 13 mcg/mL may be excellent for one person but too low for another person who usually remains seizure-free at 18 mcg/mL.
Therapeutic drug monitoring also works best when it is paired with the right clinical markers. A person taking valproic acid may need platelet counts and liver-related tests. Someone taking carbamazepine may need sodium and blood counts. Someone taking phenytoin may need albumin, free phenytoin, or liver-related testing in selected cases. A broader therapeutic drug monitoring panel may be used when several narrow-range medicines are being checked at the same time.
Therapeutic Ranges and Toxic Patterns
Therapeutic ranges are useful starting points, but they are not safety guarantees. They are affected by the lab method, formulation, timing of the blood draw, protein binding, age, pregnancy, organ function, and drug interactions.
| Medication | Common therapeutic range | When toxicity becomes more likely | Important interpretation note |
|---|---|---|---|
| Carbamazepine | About 4–12 mcg/mL | More likely above the upper range; severe toxicity often occurs at much higher levels | Active epoxide metabolite can contribute to symptoms, especially with interactions |
| Phenytoin, total | About 10–20 mcg/mL | Neurologic toxicity often becomes more likely above 20 mcg/mL | Total level can mislead when albumin is low, kidney failure is present, or interacting drugs are used |
| Phenytoin, free | About 1–2 mcg/mL | More likely above the upper range | Free level reflects active unbound drug more directly |
| Valproic acid, total | Often about 50–100 mcg/mL for epilepsy; some settings use up to 125 mcg/mL | Risk rises as levels climb, especially with symptoms or metabolic abnormalities | Free valproate may be more helpful when albumin is low or total level does not fit symptoms |
Carbamazepine toxicity often causes dizziness, double vision, drowsiness, nausea, vomiting, poor coordination, tremor, and confusion. Severe poisoning can cause abnormal heart rhythms, low blood pressure, seizures, coma, or breathing problems. A routine carbamazepine result usually measures the parent drug, but carbamazepine is also converted into carbamazepine-10,11-epoxide, an active metabolite. Some people can have toxicity symptoms that seem stronger than expected from the parent carbamazepine level alone.
Phenytoin toxicity is usually neurologic. Early signs can include nystagmus, which is repetitive eye movement seen on exam. Higher exposure can cause unsteady walking, slurred speech, tremor, confusion, severe sleepiness, and in extreme cases coma. Phenytoin is unusual because small dose increases can cause unexpectedly large level increases once the body’s metabolic pathway starts to saturate. This is why phenytoin dose adjustments are often made carefully and then rechecked.
Valproic acid toxicity can cause sleepiness, tremor, dizziness, nausea, vomiting, confusion, low body temperature, metabolic acidosis, high ammonia, low platelets, liver injury, pancreatitis, and in severe overdose coma. A person may have significant valproate-related symptoms even when the total level does not look dramatically high, especially if the free fraction is increased.
For medication-specific testing, related articles such as carbamazepine blood test interpretation, phenytoin blood test interpretation, and valproic acid blood test interpretation can help separate the individual drug patterns.
Timing and Sampling Issues
Timing can make a seizure medication level look falsely high, falsely low, or hard to compare with past results. The same person taking the same dose can have different numbers depending on whether the sample was drawn soon after a dose, halfway through the dosing interval, or right before the next dose.
For long-term monitoring, a trough level is usually preferred. A trough is drawn shortly before the next scheduled dose, when the medication concentration is near its lowest point. This timing makes it easier to compare one result with another.
A random level can still be useful in certain situations. If someone arrives in the emergency department confused, very sleepy, vomiting, or unable to walk normally, a random level may help detect toxicity. If a person has a breakthrough seizure and the clinician needs to know whether the level is very low, a random level may still provide important information. The limitation is that random levels are harder to compare with routine therapeutic ranges.
Steady state also matters. After starting a drug or changing a dose, the blood level usually needs time to settle. Testing too soon can underestimate the eventual level. The needed time varies by drug, dose, formulation, age, liver function, kidney function, and interacting medicines. Carbamazepine is especially tricky because it can speed up its own metabolism over time, a process called autoinduction. A level checked early after starting carbamazepine may not predict the later maintenance level.
Sampling problems can also affect results. A level may be misleading if the blood is drawn from a line recently used to give the medicine, if the dose time was recorded incorrectly, or if the person took an extra dose right before testing. Documentation matters. A useful lab order or clinic note should include the current dose, dose schedule, time of last dose, time of blood draw, formulation, missed doses, and reason for testing.
Formulation changes can also shift levels. Extended-release carbamazepine, delayed-release divalproex, sprinkle capsules, liquid formulations, and brand-to-generic changes may produce different peak and trough patterns. A person may feel side effects at peak levels even when the trough looks acceptable. In that case, the clinician may adjust the schedule, change the formulation, or check levels at a different time.
Interpreting Low, Normal, and High Results
A low seizure medication level means the measured concentration is below the lab’s expected therapeutic range. It does not automatically prove that the dose is wrong, but it raises the chance of inadequate seizure protection, especially if the person has had recent breakthrough seizures.
Common reasons for a low level include missed doses, delayed refills, vomiting or diarrhea, poor absorption, a recent dose decrease, pregnancy-related clearance changes, or a new medication that speeds metabolism. Carbamazepine itself can lower levels of some other drugs by increasing liver enzyme activity. Other enzyme-inducing antiseizure medicines can lower levels of valproate or other medications.
A normal level means the result falls within the lab’s listed range. This is reassuring only if the person is also doing well clinically. A normal level with ongoing seizures may mean the individual needs a different target level, a different medicine, better adherence, a review of seizure type, or evaluation for non-epileptic events. A normal level with side effects may mean the person is sensitive to the medication, the free level is high, the timing missed a peak, or another condition is causing the symptoms.
A high level means the result is above the expected range. High levels deserve closer attention when symptoms are present. Mildly high results in a person with no symptoms may be managed differently from high results in a person with confusion, falls, severe vomiting, abnormal eye movements, slurred speech, jaundice, or worsening seizures.
| Result pattern | Common meaning | Follow-up often considered |
|---|---|---|
| Low level with seizures | Underexposure is possible | Review missed doses, timing, interactions, formulation, and recent illness |
| Low level without seizures | May be acceptable for that person | Compare with prior stable levels before changing dose |
| Therapeutic level with seizures | Range may not fit the individual, or seizures may have another trigger | Review seizure type, adherence, sleep, alcohol, illness, and medication plan |
| Therapeutic level with side effects | Free drug, peak level, or sensitivity may explain symptoms | Consider free level, albumin, timing, and other causes |
| High level without symptoms | May still require review, but urgency varies | Recheck timing, dose, formulation, and trend |
| High level with symptoms | Toxicity is possible | Prompt clinical contact or urgent care depending on severity |
Dose changes should not be based on the number alone. The safest next step depends on seizure control, toxicity symptoms, how far outside the range the result is, and whether the level was drawn correctly. Stopping seizure medication suddenly can trigger serious seizures, including status epilepticus. Dose changes are usually planned and supervised.
Drug-Specific Patterns
Carbamazepine
Carbamazepine levels are often checked when seizures continue, side effects appear, adherence is uncertain, pregnancy changes drug handling, or interacting medicines are added. The common therapeutic range is about 4–12 mcg/mL, but some people do well outside that range.
Carbamazepine is metabolized in the liver, mainly through CYP3A-related pathways, and forms an active epoxide metabolite. This matters because interactions can raise either the parent drug, the metabolite, or both. Symptoms can include dizziness, double vision, sleepiness, nausea, vomiting, unsteady walking, and confusion. In more serious toxicity, heart rhythm and nervous system effects become more concerning.
Carbamazepine can also lower sodium, especially in older adults or people taking diuretics. Low sodium can cause fatigue, headache, confusion, falls, and seizures, which may be mistaken for poor seizure control. This is one reason a clinician may check electrolytes along with the drug level. A basic electrolyte panel can help show whether sodium or acid-base changes are contributing to symptoms.
Carbamazepine can also affect white blood cells, platelets, and liver-related markers. A complete blood count and liver panel may be ordered periodically or when symptoms suggest a problem.
Phenytoin
Phenytoin needs especially careful interpretation because it has nonlinear kinetics. At lower levels, the body can often clear extra drug predictably. As levels rise, the main metabolic pathway can become saturated. Once that happens, a small dose increase can cause a much larger level increase than expected.
Total phenytoin is commonly interpreted against a range of about 10–20 mcg/mL. Free phenytoin, often about 1–2 mcg/mL, is the active unbound portion. In many healthy adults with normal albumin, total phenytoin is a reasonable guide. But total phenytoin can mislead when albumin is low, kidney disease is present, liver disease is present, pregnancy is present, or another highly protein-bound drug is competing for binding sites.
Low albumin can make the total phenytoin level look low or acceptable while the free level is actually therapeutic or high. In that situation, increasing the dose based only on the total level may cause toxicity. Albumin-related interpretation is one reason clinicians sometimes compare phenytoin with protein and liver markers, including tests discussed in albumin blood test interpretation.
Phenytoin toxicity often appears as eye movement changes, dizziness, ataxia, slurred speech, tremor, confusion, and severe sleepiness. Long-term use can also affect gums, bone health, vitamin D metabolism, nerves, and appearance. These chronic effects are not always predicted by a single blood level.
Valproic Acid
Valproic acid is used for several seizure types and also for some non-seizure conditions. For epilepsy, many labs list a therapeutic range around 50–100 mcg/mL, while some contexts use an upper range of 125 mcg/mL. The correct target depends on the indication, seizure control, side effects, and the clinician’s plan.
Valproate is highly protein-bound, but binding becomes less predictable when albumin is low or when levels are high. As binding sites become saturated, the free active fraction can rise more than expected. This means the total valproic acid level may not fully reflect toxicity risk in certain patients. Free valproate can be useful when symptoms do not match the total result, albumin is low, kidney disease is present, critical illness is present, or several protein-bound drugs are being used.
Valproate can affect the liver, pancreas, platelets, ammonia level, and metabolism. Concerning symptoms include unusual sleepiness, confusion, repeated vomiting, belly pain, yellowing of the skin or eyes, easy bruising, bleeding, worsening tremor, or sudden behavior change. A clinician may order liver enzymes, bilirubin, platelet count, ammonia, lipase, or other tests depending on symptoms. Liver-related follow-up may overlap with a hepatic function panel.
Valproate has important pregnancy-related risks. People who could become pregnant should have medication plans reviewed carefully with their clinician before pregnancy whenever possible. The safest seizure plan depends on the seizure type, prior medication response, pregnancy risk, and alternatives.
What Can Change Medication Levels
Seizure medication levels change when the body absorbs, distributes, metabolizes, binds, or clears the drug differently. The most common reason is missed or inconsistent dosing, but it is far from the only reason.
Drug interactions are a major issue. Some medicines slow metabolism and raise levels. Others speed metabolism and lower levels. Carbamazepine is a strong enzyme inducer, so it can lower the effectiveness of many medicines, including some hormonal contraceptives, anticoagulants, psychiatric medicines, and other antiseizure medications. Phenytoin is also an enzyme inducer and has many interactions. Valproate can inhibit some metabolic pathways and can increase levels or effects of certain other antiseizure medicines.
Common interaction categories include:
- Antibiotics and antifungals
- Some antidepressants and antipsychotics
- Blood thinners
- Hormonal contraceptives
- Other antiseizure medicines
- HIV, tuberculosis, and transplant medicines
- Alcohol and some sedating drugs
- Herbal products such as St. John’s wort
Protein binding changes are especially important for phenytoin and valproate. Albumin is the main blood protein that binds many medications. When albumin is low, the free active portion can rise even if the total drug level looks ordinary. Low albumin may occur with liver disease, kidney protein loss, inflammation, malnutrition, pregnancy, critical illness, or major surgery.
Pregnancy can change medication levels through increased blood volume, altered protein binding, and faster clearance of some drugs. Levels may fall during pregnancy and rise again after delivery. This can create both seizure risk and toxicity risk if doses are not reviewed at the right times.
Age also matters. Older adults may develop toxicity at lower levels because of changes in liver metabolism, protein binding, balance, cognition, sodium regulation, and sensitivity to sedating effects. Children may clear some medicines differently than adults and may need weight-based dosing.
Illness can shift levels quickly. Vomiting may reduce absorption. Fever, dehydration, kidney dysfunction, liver inflammation, and poor oral intake can all change the risk picture. A person who was stable for months can become toxic during an acute illness without any intentional dose change.
Formulation and administration habits matter too. Crushing an extended-release product, switching from tablets to liquid, taking doses with or without enteral tube feeds, or changing brands can alter exposure. Any unexpected level should be interpreted alongside exactly how the medication is being taken.
Follow-Up Testing and Safety
Follow-up testing depends on the drug, symptoms, medical history, and reason for monitoring. A seizure medication level is often just one part of the safety picture.
For carbamazepine, clinicians may check:
- Carbamazepine level
- Sodium and other electrolytes
- Complete blood count
- Liver enzymes and bilirubin
- Carbamazepine-10,11-epoxide in selected cases
For phenytoin, clinicians may check:
- Total phenytoin level
- Free phenytoin level when protein binding may be abnormal
- Albumin
- Liver-related markers
- Kidney function when interpretation is complicated
- Vitamin D or bone-related follow-up during long-term therapy in selected patients
For valproic acid, clinicians may check:
- Total valproic acid level
- Free valproic acid level in selected cases
- Platelet count
- Liver enzymes and bilirubin
- Ammonia when confusion, lethargy, vomiting, or encephalopathy is suspected
- Lipase or pancreatic tests if severe abdominal symptoms occur
The timing of repeat testing depends on the clinical situation. After a planned dose change, the clinician may wait until the level is expected to be near steady state. After suspected toxicity, severe symptoms, overdose, or organ dysfunction, testing may be repeated much sooner. In emergencies, the trend can matter as much as a single result.
Safety symptoms should not be ignored just because a result is near the therapeutic range. Contact a clinician promptly for new or worsening confusion, severe sleepiness, falls, slurred speech, severe unsteadiness, fainting, repeated vomiting, yellow skin or eyes, unusual bruising or bleeding, severe rash, fever with sore throat, severe abdominal pain, or worsening seizures.
Emergency care is appropriate for prolonged seizures, repeated seizures without recovery, trouble breathing, severe confusion, coma-like sleepiness, suspected overdose, chest pain, severe allergic reaction, or a seizure in water or after major injury.
Medication plans should also account for lifestyle and adherence. A complex dosing schedule may produce unstable levels even when the prescribed dose is correct. Pill organizers, refill synchronization, phone reminders, simplified dosing schedules, and clear rescue-medication instructions can reduce preventable swings.
Common Mistakes and Next Steps
One common mistake is treating the therapeutic range as a universal target. The range is a guide, not a personal guarantee. A person’s best level is the one that controls seizures with acceptable side effects.
Another mistake is interpreting a result without knowing when the blood was drawn. A level drawn one hour after a dose cannot be compared fairly with a trough drawn before the next dose. If the timing is unclear, the result may still be useful, but it should be labeled as limited.
A third mistake is ignoring free drug levels when protein binding is abnormal. This is especially important for phenytoin and valproic acid. Low albumin, kidney failure, pregnancy, critical illness, older age, and interacting drugs can make total levels less reliable.
A fourth mistake is increasing phenytoin too aggressively. Because phenytoin metabolism can saturate, a small dose change can produce a large concentration change. This is one reason phenytoin adjustments are often made in small steps with repeat levels and symptom checks.
A fifth mistake is assuming side effects mean the level must be high. Some side effects occur at therapeutic levels, and some symptoms blamed on medication are actually caused by low sodium, liver injury, infection, sleep deprivation, alcohol, other sedatives, or a different neurologic problem.
A practical way to prepare for follow-up is to bring the information that makes the level interpretable:
- Exact medication name and formulation
- Dose strength and schedule
- Time of the last dose
- Time the blood sample was drawn
- Missed, late, doubled, or vomited doses
- Recent medication changes, including antibiotics, supplements, and over-the-counter drugs
- Recent seizures, side effects, illness, alcohol use, or pregnancy changes
- Prior levels from periods of good seizure control
The next step after an abnormal level may be a repeat trough, a free level, a dose adjustment, a formulation change, interaction review, safety labs, or a broader reassessment of the seizure treatment plan. The right response depends on whether the person is having seizures, side effects, both, or neither.
Seizure medication monitoring works best when it is consistent. Draw levels at comparable times, record dose timing accurately, and interpret the result with the person’s symptoms and seizure pattern. The lab number is important, but the safest decisions come from matching the number to the whole clinical picture.
References
- Epilepsies in children, young people and adults 2022 (Guideline)
- Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data 2022 (Systematic Review)
- Carbamazepine 2024 (Official Page)
- Phenytoin 2024 (Official Page)
- Valproic Acid 2024 (Official Page)
- Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child 2023 (Systematic Review)
Disclaimer
Carbamazepine, phenytoin, and valproic acid levels should be interpreted by a qualified clinician who knows the dose, timing, symptoms, seizure history, and other medical conditions. Do not stop or change seizure medication based only on a lab result unless your clinician tells you to do so. Seek urgent care for severe toxicity symptoms, suspected overdose, prolonged seizures, repeated seizures, breathing trouble, severe confusion, or loss of consciousness.
